TEVA PHARMACEUTICAL-SP ADR (TEVA) Fundamental Analysis & Valuation

NYSE:TEVA • US8816242098

Current stock price

31.98 USD
+0.72 (+2.3%)
Last:

This TEVA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. TEVA Profitability Analysis

1.1 Basic Checks

  • In the past year TEVA was profitable.
  • In the past year TEVA had a positive cash flow from operations.
  • In multiple years TEVA reported negative net income over the last 5 years.
  • In the past 5 years TEVA always reported a positive cash flow from operatings.
TEVA Yearly Net Income VS EBIT VS OCF VS FCFTEVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5B -10B -15B

1.2 Ratios

  • TEVA has a Return On Assets of 3.46%. This is amongst the best in the industry. TEVA outperforms 83.25% of its industry peers.
  • TEVA's Return On Equity of 17.81% is amongst the best of the industry. TEVA outperforms 90.05% of its industry peers.
  • TEVA has a Return On Invested Capital of 12.03%. This is amongst the best in the industry. TEVA outperforms 91.10% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for TEVA is below the industry average of 13.11%.
  • The 3 year average ROIC (10.53%) for TEVA is below the current ROIC(12.03%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.46%
ROE 17.81%
ROIC 12.03%
ROA(3y)-0.66%
ROA(5y)-1.34%
ROE(3y)-6.71%
ROE(5y)-9.48%
ROIC(3y)10.53%
ROIC(5y)9.34%
TEVA Yearly ROA, ROE, ROICTEVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • TEVA has a better Profit Margin (8.16%) than 84.29% of its industry peers.
  • Looking at the Operating Margin, with a value of 24.09%, TEVA belongs to the top of the industry, outperforming 92.15% of the companies in the same industry.
  • In the last couple of years the Operating Margin of TEVA has grown nicely.
  • TEVA's Gross Margin of 52.72% is fine compared to the rest of the industry. TEVA outperforms 64.40% of its industry peers.
  • In the last couple of years the Gross Margin of TEVA has grown nicely.
Industry RankSector Rank
OM 24.09%
PM (TTM) 8.16%
GM 52.72%
OM growth 3Y3.96%
OM growth 5Y4.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.99%
GM growth 5Y2.49%
TEVA Yearly Profit, Operating, Gross MarginsTEVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. TEVA Health Analysis

2.1 Basic Checks

  • TEVA has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for TEVA has been increased compared to 1 year ago.
  • Compared to 5 years ago, TEVA has more shares outstanding
  • Compared to 1 year ago, TEVA has an improved debt to assets ratio.
TEVA Yearly Shares OutstandingTEVA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B
TEVA Yearly Total Debt VS Total AssetsTEVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B

2.2 Solvency

  • Based on the Altman-Z score of 0.97, we must say that TEVA is in the distress zone and has some risk of bankruptcy.
  • TEVA's Altman-Z score of 0.97 is in line compared to the rest of the industry. TEVA outperforms 50.79% of its industry peers.
  • The Debt to FCF ratio of TEVA is 14.64, which is on the high side as it means it would take TEVA, 14.64 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 14.64, TEVA is in the better half of the industry, outperforming 76.96% of the companies in the same industry.
  • TEVA has a Debt/Equity ratio of 1.90. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 1.90, TEVA is not doing good in the industry: 80.10% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.9
Debt/FCF 14.64
Altman-Z 0.97
ROIC/WACC1.49
WACC8.08%
TEVA Yearly LT Debt VS Equity VS FCFTEVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.3 Liquidity

  • TEVA has a Current Ratio of 1.04. This is a normal value and indicates that TEVA is financially healthy and should not expect problems in meeting its short term obligations.
  • TEVA's Current ratio of 1.04 is on the low side compared to the rest of the industry. TEVA is outperformed by 85.86% of its industry peers.
  • TEVA has a Quick Ratio of 1.04. This is a bad value and indicates that TEVA is not financially healthy enough and could expect problems in meeting its short term obligations.
  • TEVA's Quick ratio of 0.80 is on the low side compared to the rest of the industry. TEVA is outperformed by 84.29% of its industry peers.
Industry RankSector Rank
Current Ratio 1.04
Quick Ratio 0.8
TEVA Yearly Current Assets VS Current LiabilitesTEVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. TEVA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 17.27% over the past year.
  • The Earnings Per Share has been growing slightly by 4.89% on average over the past years.
  • The Revenue has been growing slightly by 4.32% in the past year.
  • The Revenue has been growing slightly by 0.71% on average over the past years.
EPS 1Y (TTM)17.27%
EPS 3Y4.89%
EPS 5YN/A
EPS Q2Q%35.21%
Revenue 1Y (TTM)4.32%
Revenue growth 3Y4.96%
Revenue growth 5Y0.71%
Sales Q2Q%11.4%

3.2 Future

  • TEVA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.21% yearly.
  • The Revenue is expected to grow by 1.74% on average over the next years.
EPS Next Y-6.32%
EPS Next 2Y3.42%
EPS Next 3Y6.21%
EPS Next 5YN/A
Revenue Next Year-2.05%
Revenue Next 2Y0.56%
Revenue Next 3Y1.74%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TEVA Yearly Revenue VS EstimatesTEVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 5B 10B 15B 20B
TEVA Yearly EPS VS EstimatesTEVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2020 2021 2022 2023 2024 2025 2026 2027 2028 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

8

4. TEVA Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 10.88, the valuation of TEVA can be described as very reasonable.
  • TEVA's Price/Earnings ratio is rather cheap when compared to the industry. TEVA is cheaper than 91.10% of the companies in the same industry.
  • TEVA is valuated cheaply when we compare the Price/Earnings ratio to 27.53, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 11.62, which indicates a very decent valuation of TEVA.
  • Based on the Price/Forward Earnings ratio, TEVA is valued cheaply inside the industry as 86.39% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 37.95. TEVA is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 10.88
Fwd PE 11.62
TEVA Price Earnings VS Forward Price EarningsTEVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 89.01% of the companies in the same industry are more expensive than TEVA, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, TEVA is valued cheaper than 82.72% of the companies in the same industry.
Industry RankSector Rank
P/FCF 32.44
EV/EBITDA 9.62
TEVA Per share dataTEVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

  • The excellent profitability rating of TEVA may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.42%
EPS Next 3Y6.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TEVA Dividend Analysis

5.1 Amount

  • TEVA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TEVA Fundamentals: All Metrics, Ratios and Statistics

TEVA PHARMACEUTICAL-SP ADR

NYSE:TEVA (4/17/2026, 10:15:09 AM)

31.98

+0.72 (+2.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-28
Earnings (Next)04-29
Inst Owners21.22%
Inst Owner Change0%
Ins Owners0.47%
Ins Owner Change13.72%
Market Cap37.25B
Revenue(TTM)17.26B
Net Income(TTM)1.41B
Analysts82.86
Price Target0.11 (-99.66%)
Short Float %2.37%
Short Ratio3.52
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.53%
Min EPS beat(2)16.51%
Max EPS beat(2)38.54%
EPS beat(4)4
Avg EPS beat(4)16.39%
Min EPS beat(4)4.65%
Max EPS beat(4)38.54%
EPS beat(8)7
Avg EPS beat(8)8.31%
EPS beat(12)9
Avg EPS beat(12)5.55%
EPS beat(16)10
Avg EPS beat(16)3.14%
Revenue beat(2)2
Avg Revenue beat(2)3.32%
Min Revenue beat(2)0.9%
Max Revenue beat(2)5.75%
Revenue beat(4)2
Avg Revenue beat(4)-0.7%
Min Revenue beat(4)-4.77%
Max Revenue beat(4)5.75%
Revenue beat(8)5
Avg Revenue beat(8)0.11%
Revenue beat(12)8
Avg Revenue beat(12)1.11%
Revenue beat(16)8
Avg Revenue beat(16)-0.59%
PT rev (1m)-0.83%
PT rev (3m)1.9%
EPS NQ rev (1m)-1.25%
EPS NQ rev (3m)-6.41%
EPS NY rev (1m)-2.16%
EPS NY rev (3m)-2.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.2%
Revenue NY rev (1m)-1.07%
Revenue NY rev (3m)-2.56%
Valuation
Industry RankSector Rank
PE 10.88
Fwd PE 11.62
P/S 2.16
P/FCF 32.44
P/OCF 22.59
P/B 4.71
P/tB N/A
EV/EBITDA 9.62
EPS(TTM)2.94
EY9.19%
EPS(NY)2.75
Fwd EY8.61%
FCF(TTM)0.99
FCFY3.08%
OCF(TTM)1.42
OCFY4.43%
SpS14.82
BVpS6.79
TBVpS-10.19
PEG (NY)N/A
PEG (5Y)N/A
Graham Number21.1962 (-33.72%)
Profitability
Industry RankSector Rank
ROA 3.46%
ROE 17.81%
ROCE 15.24%
ROIC 12.03%
ROICexc 13.83%
ROICexgc 82.57%
OM 24.09%
PM (TTM) 8.16%
GM 52.72%
FCFM 6.65%
ROA(3y)-0.66%
ROA(5y)-1.34%
ROE(3y)-6.71%
ROE(5y)-9.48%
ROIC(3y)10.53%
ROIC(5y)9.34%
ROICexc(3y)11.98%
ROICexc(5y)10.44%
ROICexgc(3y)70.07%
ROICexgc(5y)58.35%
ROCE(3y)13.34%
ROCE(5y)11.83%
ROICexgc growth 3Y24.16%
ROICexgc growth 5Y15.53%
ROICexc growth 3Y17.63%
ROICexc growth 5Y14.52%
OM growth 3Y3.96%
OM growth 5Y4.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.99%
GM growth 5Y2.49%
F-Score8
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 1.9
Debt/FCF 14.64
Debt/EBITDA 2.91
Cap/Depr 50%
Cap/Sales 2.9%
Interest Coverage 4.38
Cash Conversion 31.96%
Profit Quality 81.48%
Current Ratio 1.04
Quick Ratio 0.8
Altman-Z 0.97
F-Score8
WACC8.08%
ROIC/WACC1.49
Cap/Depr(3y)47.55%
Cap/Depr(5y)45.36%
Cap/Sales(3y)3.08%
Cap/Sales(5y)3.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.27%
EPS 3Y4.89%
EPS 5YN/A
EPS Q2Q%35.21%
EPS Next Y-6.32%
EPS Next 2Y3.42%
EPS Next 3Y6.21%
EPS Next 5YN/A
Revenue 1Y (TTM)4.32%
Revenue growth 3Y4.96%
Revenue growth 5Y0.71%
Sales Q2Q%11.4%
Revenue Next Year-2.05%
Revenue Next 2Y0.56%
Revenue Next 3Y1.74%
Revenue Next 5YN/A
EBIT growth 1Y17.36%
EBIT growth 3Y9.12%
EBIT growth 5Y5.49%
EBIT Next Year16.89%
EBIT Next 3Y10.65%
EBIT Next 5YN/A
FCF growth 1Y53.27%
FCF growth 3Y3.28%
FCF growth 5Y12.47%
OCF growth 1Y32.24%
OCF growth 3Y1.22%
OCF growth 5Y6.28%

TEVA PHARMACEUTICAL-SP ADR / TEVA Fundamental Analysis FAQ

What is the fundamental rating for TEVA stock?

ChartMill assigns a fundamental rating of 5 / 10 to TEVA.


What is the valuation status of TEVA PHARMACEUTICAL-SP ADR (TEVA) stock?

ChartMill assigns a valuation rating of 8 / 10 to TEVA PHARMACEUTICAL-SP ADR (TEVA). This can be considered as Undervalued.


What is the profitability of TEVA stock?

TEVA PHARMACEUTICAL-SP ADR (TEVA) has a profitability rating of 8 / 10.


Can you provide the PE and PB ratios for TEVA stock?

The Price/Earnings (PE) ratio for TEVA PHARMACEUTICAL-SP ADR (TEVA) is 10.88 and the Price/Book (PB) ratio is 4.71.


What is the financial health of TEVA PHARMACEUTICAL-SP ADR (TEVA) stock?

The financial health rating of TEVA PHARMACEUTICAL-SP ADR (TEVA) is 2 / 10.